<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dactinomycin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dactinomycin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dactinomycin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11201" href="/d/html/11201.html" rel="external">see "Dactinomycin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13202" href="/d/html/13202.html" rel="external">see "Dactinomycin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F156394"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cosmegen [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866494"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cosmegen</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F156432"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antibiotic</li></ul></div>
<div class="block doa drugH1Div" id="F156398"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Dactinomycin may be prescribed in MICROgrams (eg, 150 mcg), although many regimens list the dose in MILLIgrams (eg, mg/kg or mg/m<sup>2</sup>).</b> Reduce the dactinomycin dose by 50% during concomitant radiation. Dactinomycin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (Basch 2011). Calculate the dose for obese or edematous patients based on ideal body weight (manufacturer's labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Ewing sarcoma: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAIA regimen:</i> Adults ≤35 years of age: 500 mcg/m<sup>2</sup>/dose for 3 days (dactinomycin alternates with doxorubicin) every 3 weeks for 14 cycles (in combination with vincristine, ifosfamide, and mesna) (Paulussen 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAC/IE regimen:</i> Adults ≤30 years: 1,250 mcg/m<sup>2</sup> on day 1 of each odd-numbered 21-day cycle (dactinomycin is substituted for doxorubicin after a maximum doxorubicin dose is reached; in combination with vincristine, cyclophosphamide, and mesna; alternating with IE [ifosfamide, mesna, and etoposide] on even-numbered cycles); continue through cycle 17 (Grier 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i> 1,250 mcg/m<sup>2</sup> once every 3 weeks for 51 weeks (as part of a combination chemotherapy regimen).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd37b45c-f0bf-42b1-93a9-91edf9f9dd3e">Gestational trophoblastic neoplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonmetastatic or metastatic low-risk disease:</i> 1.25 <b>mg</b>/m<sup>2</sup> every 2 weeks as a single agent; continue until human chorionic gonadotropin (hCG) level normalizes (Osborne 2011) <b>or</b> (manufacturer's labeling) 12 mcg/kg/day for 5 days (as a single agent).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic high-risk disease (off-label dosing): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>EMA-CO regimen: </i>500 mcg/dose on days 1 and 2 every 2 weeks (in combination with etoposide, methotrexate, leucovorin, cyclophosphamide, and vincristine); continue for at least 2 treatment cycles after a normal hCG level (Escobar 2003; Lurain 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>EMA-EP regimen:</i> 500 mcg/dose on days 1 and 2 every 2 weeks (in combination with etoposide, methotrexate, leucovorin, and cisplatin); continue for 2 to 4 treatment cycles after a normal hCG level (Ghaemmaghami 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>EP-EMA regimen:</i> EMA: 500 mcg/dose on day 1 every 2 weeks (in combination with etoposide, methotrexate, and leucovorin); alternating weekly with EP (etoposide and cisplatin) (Newlands 2000).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Manufacturer's labeling:</i> 500 mcg/dose on days 1 and 2 every 2 weeks for up to 8 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a8f2dab-e7cd-4a3d-9784-cb1523635595">Ovarian germ cell tumors, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian germ cell tumors, malignant (off-label use):</b>
<b>IV:</b> VAC regimen: 500 mcg daily for 5 days every 4 weeks (in combination with vincristine and cyclophosphamide) for ~1 year (Gershenson 1985) <b>or</b> 300 mcg/m<sup>2</sup>/day for 5 days every 4 weeks (in combination with vincristine and cyclophosphamide) for at least 10 cycles (Slayton 1985).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae32a1ce-f896-4327-a8da-63ddddae9f5f">Regional perfusion in solid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Regional perfusion</b>
<b>in solid tumors </b>(dosages and techniques may vary by institution; in combination with melphalan): Manufacturer's labeling: Lower extremity or pelvis: 50 mcg/kg once; upper extremity: 35 mcg/kg once.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Regional limb perfusion: Soft tissue sarcoma, locally advanced/unresectable:</b> Isolated limb infusion protocol: 50 to 100 mcg/L of tissue in 400 mL warmed, heparinized NS (in combination with melphalan) over 20 to 30 minutes (Moncrieff 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAC regimen:</i> Patients &lt;50 years of age: 45 mcg/kg (maximum dose: 2,500 mcg) every 3 weeks; duration of therapy depends on risk status (in combination with vincristine and cyclophosphamide, and mesna); dose omission required following radiation therapy (Raney 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VA regimen:</i> Patients &lt;50 years of age: 45 mcg/kg (maximum dose: 2,500 mcg) every 3 weeks for ~1 year (in combination with vincristine); dose omission required following radiation therapy (Raney 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i> Dosing in the prescribing information may not reflect current clinical practice; 15 mcg/kg/day for 5 days every 3 to 9 weeks for up to 112 weeks (as part of a combination chemotherapy regimen).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8cead17-5b33-4326-9157-7fee0fdfa8f5">Wilms tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAD regimen (preoperative induction):</i> Patients &lt;30 years of age: IV: 45 mcg/kg/dose (maximum: 2,300 mcg/dose) on day 1 of weeks 1, 4, 7, and 10 (in combination with vincristine and doxorubicin) (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DD-4A regimen (postoperative):</i> Patients &lt;30 years of age: 45 mcg/kg/dose (maximum dose: 2,300 mcg/dose) on day 1 of weeks 1, 7, 13, 19, and 25 (in combination with vincristine, doxorubicin, and radiation). <b>Note:</b> The first dose of dactinomycin administered following whole lung or whole abdomen irradiation should be decreased by 50% (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EE-4A regimen (pre- or postoperative):</i> Patients &lt;30 years: 45 mcg/kg/dose (maximum dose: 2,300 mcg/dose) on day 1 of weeks 1, 4, 7, 10, 13, 16, and 19 (in combination with vincristine) (Ehrlich 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i> 45 mcg/kg once every 3 to 6 weeks for up to 26 weeks (as part of a combination chemotherapy regimen).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991772"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on the amount of urinary excretion, dosage adjustments may not be necessary (Kintzel 1995).</p></div>
<div class="block doha drugH1Div" id="F50988922"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>The following adjustments have also been recommended: </i>Any transaminase increase: Reduce dose by 50%; may increase by monitoring toxicities (Floyd 2006).</p></div>
<div class="block doo drugH1Div" id="F20340170"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>ASCO Guidelines for appropriate chemotherapy dosing in adults with cancer</i>
<i> with a BMI ≥30 kg/m<sup>2</sup></i>
<i>: </i>Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).<b> Note:</b> The manufacturer's labeling recommends using ideal body weight to calculate the dose for patients with obesity or who are edematous.</p></div>
<div class="block dot drugH1Div" id="F49116152"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mucocutaneous reaction, severe: Permanently discontinue dactinomycin.</p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppression, severe: Consider treatment delay or dose reduction in patients with prolonged myelosuppression based on the reaction severity and the disease being treated.</p>
<p style="text-indent:-2em;margin-left:2em;">Sinusoidal obstruction syndrome (SOS, also known as veno-occlusive disease): If SOS develops, consider delaying the next dactinomycin dose. Resume, reduce dose, or permanently discontinue dactinomycin based on the reaction severity and the disease being treated.</p>
<p style="text-indent:-2em;margin-left:2em;">Concurrent radiation therapy: May require dactinomycin dose reduction (50%) or dose omission; refer to specific protocol.</p></div>
<div class="block doe drugH1Div" id="F156399"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F156417"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13202" href="/d/html/13202.html" rel="external">see "Dactinomycin: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: Medication orders for dactinomycin are commonly written in MICROgrams (eg, mcg/kg, mcg/m<sup>2</sup>) although many regimens list the dose in MILLIgrams (eg, mg/kg or mg/m<sup>2</sup>); use extra precaution.</b> The dose intensity per 2-week cycle for adults and children should not exceed 15 mcg/kg/day for 5 days or 400 to 600 mcg/<b>m<sup>2</sup></b>/day for 5 days. The manufacturer recommends calculation of the dosage for obese or edematous adult patients on the basis of body surface area in an effort to relate dosage to lean body mass. Antiemetics are recommended to prevent nausea and vomiting; dactinomycin is associated with a moderate or high emetic potential (depending on dose) in pediatrics (POGO [Paw Cho Sing 2019]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma:</b> Children and Adolescents: VAIA regimen: Limited data available: IV: 500 mcg/<b>m<sup>2</sup></b>/dose for 3 days (dactinomycin alternating with doxorubicin) every 3 weeks for 14 cycles (in combination with vincristine, ifosfamide, and mesna) (Paulussen 2008)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91f9cddf-6fc2-4e12-a5ee-c030e3e66ea9">Kaposi sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kaposi sarcoma:</b> Limited data available: Children and Adolescents: IV: 420 mcg/<b>m<sup>2</sup></b>/day for 5 days every 4 weeks (in various combination regimens) (Olweny 1974)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma:</b> VAC regimen: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 25 mcg/kg every 3 weeks, weeks 0 to 45 (in combination with vincristine and cyclophosphamide, and mesna); dose omission required following radiation therapy (Raney 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 45 mcg/kg (maximum dose: 2,500 mcg/dose) every 3 weeks, weeks 0 to 45 (in combination with vincristine and cyclophosphamide, and mesna); dose omission required following radiation therapy (Raney 2011)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8cead17-5b33-4326-9157-7fee0fdfa8f5">Wilms tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor:</b>
<b>Note:</b> Regimen selection based on multiple factors including the extent of disease at diagnosis, response to induction chemotherapy, and extent of surgical resection.</p>
<p style="text-indent:-2em;margin-left:4em;">EE-4A regimen: <b>Note:</b> If the radiation field includes the whole lung or whole abdomen, reduce dose 50% during irradiation therapy</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 23 mcg/kg/dose (maximum dose: 2,300 mcg/dose) over 1 to 5 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, and 19 (in combination with vincristine) (Ehrlich 2017)</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 45 mcg/kg/dose (maximum dose: 2,300 mcg/dose) over 1 to 5 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, and 19 (in combination with vincristine) (Ehrlich 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">VAD regimen: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 23 mcg/kg/dose (maximum dose: 2,300 mcg<b>/</b>dose) over 1 to 5 minutes on day 1 of weeks 1, 4, 7, and 10 (in combination with vincristine and doxorubicin) (Ehrlich 2017)</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 45 mcg/kg/dose (maximum dose: 2,300 mcg/dose) over 1 to 5 minutes on day 1 of weeks 1, 4, 7, and 10 (in combination with vincristine and doxorubicin) (Ehrlich 2017)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090503"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on the amount of urinary excretion, dosage adjustments may not be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51090504"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended: Children and Adolescents: Any transaminase increase: Consider dose reduction by 50%; may increase by monitoring toxicities (Floyd 2006).</p></div>
<div class="block adr drugH1Div" id="F156363"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue, malaise, peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, cheilitis, dermatitis, erythema multiforme, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth suppression, hypocalcemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, aphthous stomatitis, constipation, diarrhea, dysphagia, esophagitis, gastrointestinal ulcer, mucositis, nausea, proctitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, bone marrow depression, disseminated intravascular coagulation, febrile neutropenia, hemorrhage, leukopenia, neutropenia (nadir: 14 to 21 days), pancytopenia, reticulocytopenia, second primary malignant neoplasm (including leukemia), thrombocytopenia, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, ascites, hepatic failure, hepatic sinusoidal obstruction syndrome, hepatitis, hepatomegaly, hepatotoxicity, severe hepatic disease (hepatopathy-thrombocytopenia syndrome, Farruggia 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal function abnormality, renal failure syndrome, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis, pneumothorax</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, radiation recall phenomenon</p></div>
<div class="block coi drugH1Div" id="F156378"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F156360"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe and fatal myelosuppression (neutropenia, thrombocytopenia, and anemia) may occur. The neutrophil nadir typically occurs 14 to 21 days after administration. Obtain complete blood counts prior to each cycle; delay the next dactinomycin dose if severe myelosuppression has not improved. Based on the severity of myelosuppression and disease state being treated, consider dose reduction in patients with prolonged myelosuppression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Severe mucocutaneous toxicity, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, may occur. Permanently discontinue dactinomycin if a severe mucocutaneous reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Dactinomycin is a vesicant (Pérez Fidalgo 2012); ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Severe local tissue damage (blistering, ulcerations, and persistent pain) requiring wide excision surgery followed by split-thickness skin grafting may occur. Immediately interrupt the infusion if signs/symptoms of extravasation occur. Apply dry, cold compresses to the site of extravasation for 20 minutes, 4 times per day for 1 to 2 days (Pérez Fidalgo 2012). Monitor closely; plastic surgery consultation may be necessary if extravasation occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Dactinomycin may cause hepatotoxicity; monitor AST, ALT, alkaline phosphatase, and bilirubin prior to and during dactinomycin therapy. May also cause severe and fatal hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive liver disease); risk factors include age &lt;4 years or concomitant radiotherapy. Use with caution in hepatobiliary dysfunction. Monitor for signs or symptoms of hepatic SOS, including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt 2004). If SOS develops, consider delaying the next dactinomycin dose. May require therapy interruption, dose reduction, or permanent discontinuation (based on the severity of the reaction and disease being treated).</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Renal function abnormalities may occur with dactinomycin; monitor creatinine and electrolytes frequently during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: The risk of secondary malignancies (including leukemia) is increased with dactinomycin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation therapy recipients: Dactinomycin potentiates the effects of radiation therapy; use with caution in patients who have received radiation therapy. Reduce the dactinomycin dose by 50% in patients who are receiving dactinomycin and concomitant radiation therapy. Combination with radiation therapy may result in increased toxicity (eg, GI toxicity, myelosuppression, or erythema and vesiculation of the skin or buccal and pharyngeal mucosa). Erythema from prior radiation therapy may be reactivated by dactinomycin. Radiation recall risk appears to be highest when administered within 2 months of prior radiation, although the risk can still occur with distant radiation exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dosage expression: Dosage is usually expressed in <b>MICRO</b>grams. Calculate the dose for obese or edematous patients based on ideal body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Avoid administration of live vaccines prior to and during dactinomycin treatment.</p></div>
<div class="block foc drugH1Div" id="F156372"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosmegen: 0.5 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F156356"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323092"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cosmegen Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $3,250.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (DACTINomycin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $921.88 - $1,822.59</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866495"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosmegen: 0.5 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F156375"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Dactinomycin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (Basch 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 10 to 15 minutes; may also be administered as a slow IV push (off-label rate) in some protocols. Do not filter with cellulose ester membrane filters.</p>
<p style="text-indent:-2em;margin-left:2em;">Regional perfusion: Technique may vary by institution; consult protocol for details. Local reactions including epidermolysis, erythema, and edema have been reported (may be severe).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses for 20 minutes 4 times a day for 1 to 2 days (ESMO/EONS [Pérez Fidalgo 2012]).</p></div>
<div class="block admp drugH1Div" id="F52612478"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May administer undiluted into the side-port of a free flowing IV infusion by slow IVP over a few minutes; or may further dilute and administer as IV infusion over 10 to 15 minutes; consider a D5W or NS flush before and after a dactinomycin dose to ensure venous patency. Cellulose ester membrane filters may partially remove dactinomycin from solution and should not be used during administration. Avoid extravasation; do not give IM or SubQ.</p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics are recommended to prevent nausea and vomiting; dactinomycin is associated with a moderate or high emetic potential (depending on dose) in pediatrics (POGO [Paw Cho Sing 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses for 20 minutes 4 times a day for 1 to 2 days (Pérez Fidalgo 2012).</p></div>
<div class="block hazard drugH1Div" id="F49130968"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F156373"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma:</b> Treatment of Ewing sarcoma (as part of a multi-phase, combination chemotherapy regimen)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia:</b> Treatment of gestational trophoblastic neoplasia in post-menarchal patients (as a single agent or as part of a combination chemotherapy regimen)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma:</b> Treatment of rhabdomyosarcoma (as part of a multi-phase, combination chemotherapy regimen)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors:</b> Palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies (as a component of regional perfusion) in adult patients</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor: </b>Treatment of Wilms tumor (as part of a multi-phase, combination chemotherapy regimen)</p></div>
<div class="block off-label drugH1Div" id="F25475199"><span class="drugH1">Use: Off-Label: Adult</span><p>Ovarian germ cell tumors (malignant)</p></div>
<div class="block mst drugH1Div" id="F156441"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DACTINomycin may be confused with dacarbazine, Dacogen, DAPTOmycin, DAUNOrubicin</p>
<p style="text-indent:-2em;margin-left:4em;">Actinomycin may be confused with achromycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299119"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F156365"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49297586"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status of females of reproductive potential prior to initiating dactinomycin therapy; effective contraception should be used during therapy and for at least 6 months after the last dactinomycin dose.</p>
<p style="text-indent:0em;margin-top:2em;">When used for gestational trophoblastic neoplasm, unfavorable outcomes have been reported when subsequent pregnancies occur within 6 months of treatment. It is recommended to use effective contraception for 6 months to 1 year after therapy (Matsui 2004; Seckl 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Males with female partners of reproductive potential should use effective contraception during therapy and for 3 months after the last dactinomycin dose.</p></div>
<div class="block pri drugH1Div" id="F156380"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies and its mechanism of action, dactinomycin may cause fetal harm if administered to a pregnant female.</p>
<p style="text-indent:0em;margin-top:2em;">When used for gestational trophoblastic neoplasm, unfavorable outcomes have been reported when subsequent pregnancies occur within 6 months of treatment (Matsui 2004; Seckl 2013).</p></div>
<div class="block brc drugH1Div" id="F156381"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dactinomycin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and (based on limited data) for 14 days after the last dactinomycin dose.</p></div>
<div class="block mop drugH1Div" id="F156370"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC prior to each treatment cycle, liver function tests (eg, AST, ALT, total bilirubin, alkaline phosphatase), renal function tests, and electrolytes. Verify pregnancy status in females of reproductive potential prior to therapy initiation. Monitor for signs/symptoms of hepatic sinusoidal obstruction syndrome, including unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt 2004). Monitor for signs/symptoms of secondary malignancy, extravasation, mucocutaneous reactions, and radiation recall.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F156359"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dactinomycin binds to the guanine portion of DNA intercalating between guanine and cytosine base pairs inhibiting DNA and RNA synthesis and protein synthesis</p></div>
<div class="block phk drugH1Div" id="F156377"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Children: Extensive extravascular distribution (59 to 714 L) (Veal 2005); does not penetrate blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally hepatic (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 30 to 40 hours (Perry 2012); Children: Range: 14 to 43 hours (Veal 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: ~30% in urine and feces within 1 week</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869371"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | K.u. dactinomycin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Dactinomicina | Dactinomycina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dactinomicina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dacilon | Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen lyovac</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Actinocin | Dacilon | Dacmozen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Korea united dactinomycin | Union dactinomycin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen lyovac | Daciflo</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ac-De | Cosmegen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dacilon | Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Cosmegen lyovac | Cosmegen lyovac farma mondo | Cosmegen specific</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Trepar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dacilon | Lyovac | Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Dactinomicina</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen lyovac</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Cosmegen lyovac</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lyovac Cosmogen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen lyovac | Lyovac cosmegen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Dacilon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen lyovac | Dactol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cosmegen | Dacticin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15143082">
<a name="15143082"></a>Arndt C, Hawkins, D, Anderson JR, et al, “Age is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin and Cyclophosphamide,” <i>J Clin Oncol</i>, 2004, 22(10):1894-901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/15143082/pubmed" id="15143082" target="_blank">15143082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2852333">
<a name="2852333"></a>Bagshawe KD, "High-Risk Metastatic Trophoblastic Disease," <i>Obstet Gynecol Clin North Am</i>, 1988, 15(3):531-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/2852333/pubmed" id="2852333" target="_blank">2852333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21947834">
<a name="21947834"></a>Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/21947834/pubmed" id="21947834" target="_blank">21947834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2006077">
<a name="2006077"></a>Berg SL, Grisell DL, DeLaney TF, et al, “Principles of Treatment of Pediatric Solid Tumors,” <i>Pediatr Clin North Am</i>, 1991, 38(2):249-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/2006077/pubmed" id="2006077" target="_blank">2006077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8635004">
<a name="8635004"></a>Berkowitz RS and Goldstein DP, “Gestational Trophoblastic Disease,” <i>Cancer</i>, 1995, 76(10 Suppl):2079-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/8635004/pubmed" id="8635004" target="_blank">8635004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3357006">
<a name="3357006"></a>Carli M, Pastore G, Perilongo G, et al, “Tumor Response and Toxicity After Single High-Dose Versus Standard Five-Day Divided Dose Dactinomycin in Childhood Rhabdomyosarcoma,” <i>J Clin Oncol</i>, 1988, 6(4):654-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/3357006/pubmed" id="3357006" target="_blank">3357006</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cosmegen (dactinomycin) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28795993">
<a name="28795993"></a>Ehrlich P, Chi YY, Chintagumpala MM, et al. Results of the first prospective multi-institutional treatment study in children with bilateral Wilms tumor (AREN0534): a report from the Children's Oncology Group. <i>Ann Surg</i>. 2017;266(3):470-478. doi: 10.1097/SLA.0000000000002356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/28795993/pubmed" id="28795993" target="_blank">28795993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675675">
<a name="14675675"></a>Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. <i>Gynecol Oncol</i>. 2003;91(3):552-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/14675675/pubmed" id="14675675" target="_blank">14675675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21271778">
<a name="21271778"></a>Farruggia P, Macaluso A, Tropia S, et al. Hepatopathy-thrombocytopenia syndrome (HTS) after actinomycin-D therapy: report of three cases and review of the literature. <i>Pediatr Hematol Oncol</i>. 2011;28(3):237-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/21271778/pubmed" id="21271778" target="_blank">21271778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al, "Hepatotoxicity of Chemotherapy," <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2996746">
<a name="2996746"></a>Gershenson DM, Copeland LJ, Kavanagh JJ, et al, “Treatment of Malignant Nondysgerminomatous Germ Cell Tumors of the Ovary With Vincristine, Dactinomycin, and Cyclophosphamide,” <i>Cancer</i>, 1985, 56(12):2756-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/2996746/pubmed" id="2996746" target="_blank">2996746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15086738">
<a name="15086738"></a>Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). <i>Int J Gynecol Cancer</i>. 2004;14(2):360-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/15086738/pubmed" id="15086738" target="_blank">15086738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12697883">
<a name="12697883"></a>Goorin AM, Schwartzentruber DJ, Devidas M, et al, "Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651," <i>J Clin Oncol</i>, 2003, 21(8):1574-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/12697883/pubmed" id="12697883" target="_blank">12697883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594313">
<a name="12594313"></a>Grier HE, Krailo MD, Tarbell NJ, et al, "Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone," <i>N Engl J Med</i>, 2003, 348(8):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/12594313/pubmed" id="12594313" target="_blank">12594313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. <i>Cancer Treat Rev. </i>1995;21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24345772">
<a name="24345772"></a>Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. <i>Cancer Treat Rev</i>. 2014;40(4):523-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/24345772/pubmed" id="24345772" target="_blank">24345772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17086804">
<a name="17086804"></a>Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. <i>J Reprod Med</i>. 2006;51(10):767-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/17086804/pubmed" id="17086804" target="_blank">17086804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15305824">
<a name="15305824"></a>Matsui H, Iitsuka Y, Suzuka K, et al. Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor.<i> J Reprod Med</i>. 2004;49(7):531-534.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/15305824/pubmed" id="15305824" target="_blank">15305824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18648882">
<a name="18648882"></a>Moncrieff MD, Kroon HM, Kam PC, et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. <i>Ann Surg Oncol</i>. 2008;15(10):2749-2756.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/18648882/pubmed" id="18648882" target="_blank">18648882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10673528">
<a name="10673528"></a>Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. <i>J Clin Oncol</i>. 2000;18(4):854-859.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/10673528/pubmed" id="10673528" target="_blank">10673528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4617713">
<a name="4617713"></a>Olweny CL, Toya T, Mbidde EK, Lwanga SK. Treatment of Kaposi's sarcoma by combination of actinomycin-D, vincristine and imidazole carboxamide (nsc-45388): results of a randomized clinical trial. <i>Int J Cancer</i>. 1974;14(5):649-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/4617713/pubmed" id="4617713" target="_blank">4617713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263100">
<a name="21263100"></a>Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. <i>J Clin Oncol</i>. 2011;29(7):825-831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/21263100/pubmed" id="21263100" target="_blank">21263100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18802150">
<a name="18802150"></a>Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. <i>J Clin Oncol</i>. 2008;26(27):4385-4393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/18802150/pubmed" id="18802150" target="_blank">18802150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Perry MC, ed. Chemotherapeutic agents: dactinomycin. In: <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7799012">
<a name="7799012"></a>Pritchard J, Imeson J, Barnes J, et al, “Results of the United Kingdom Children's Cancer Study Group First Wilms' Tumor Study,” <i>J Clin Oncol</i>, 1995, 13(1):124-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/7799012/pubmed" id="7799012" target="_blank">7799012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357783">
<a name="21357783"></a>Raney RB, Walterhouse DO, Meza JL, et al, “Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group,” <i>J Clin Oncol</i>, 2011, 29(10):1312-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/21357783/pubmed" id="21357783" target="_blank">21357783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23999759">
<a name="23999759"></a>Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013 Oct;2( Suppl 6):vi39-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/23999759/pubmed" id="23999759" target="_blank">23999759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2988740">
<a name="2988740"></a>Slayton RE, Park RC, Silverberg SG, et al, “Vincristine, Dactinomycin, and Cyclophosphamide in the Treatment of Malignant Germ Cell Tumors of the Ovary. A Gynecologic Oncology Group Study (A Final Report),” <i>Cancer</i>, 1985, 56(2):243-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/2988740/pubmed" id="2988740" target="_blank">2988740</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16115931">
<a name="16115931"></a>Veal GJ, Cole M, Errington J, et al, “Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: A United Kingdom Children's Cancer Study Group Study,” <i>Clin Cancer Res</i>, 2005, 11(16):5893-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dactinomycin-drug-information/abstract-text/16115931/pubmed" id="16115931" target="_blank">16115931</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9318 Version 308.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
